EMEA reviews policy on conflicts of interest
This article was originally published in SRA
Executive Summary
Ongoing discussions on the European Medicines Agency’s policy on handling conflicts of interest relating to experts appointed to the scientific advisory groups that provide advice on specific types of medicinal products or treatments to the agency’s Committee for Medicinal Products for Human Use are likely to lead to a revision of the policy1.
You may also be interested in...
Global Regulators Issue Advice On Clinical Comparability Of Biosimilar MAbs
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Global Pharma Industry Regulators Seek Unified Approach To Remote Inspections
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Canada Boosts Postmarket Device Safety With New Reporting Rules
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: